Chronic Inflammatory Demyelinating Polyneuropathy News and Research

RSS
Influenza vaccine found to be safe for people with autoimmune neuromuscular disorders

Influenza vaccine found to be safe for people with autoimmune neuromuscular disorders

As off-label use spreads, supplies of niche drugs and patients’ patience grow short

As off-label use spreads, supplies of niche drugs and patients’ patience grow short

Neurologists identify cause of immune-mediated neuropathies

Neurologists identify cause of immune-mediated neuropathies

Chronic inflammatory demyelinating polyneuropathy commonly misdiagnosed

Chronic inflammatory demyelinating polyneuropathy commonly misdiagnosed

Novartis launches ‘24 Life Hacks in 24 hours’ showing commitment to help people with MS access guidance and advice

Novartis launches ‘24 Life Hacks in 24 hours’ showing commitment to help people with MS access guidance and advice

Intravenous immune globulin effective treatment for GBS, CIDP

Intravenous immune globulin effective treatment for GBS, CIDP

CSL Behring commences enrollment in SCIg PATH trial for CIDP

CSL Behring commences enrollment in SCIg PATH trial for CIDP

New guideline recommends plasmapheresis usage to treat people with severe relapses in MS, neuropathies

New guideline recommends plasmapheresis usage to treat people with severe relapses in MS, neuropathies

CSL Behring creates Interlaken Leadership Awards to support innovative immunoglobulin research

CSL Behring creates Interlaken Leadership Awards to support innovative immunoglobulin research

Talecris third quarter net revenue increases 2.8% to $407.0 million

Talecris third quarter net revenue increases 2.8% to $407.0 million

FDA approves Gamunex-C for primary immunodeficiency treatment

FDA approves Gamunex-C for primary immunodeficiency treatment

Phase II GAMMAGARD clinical study for Alzheimer's disease: 18-month results announced

Phase II GAMMAGARD clinical study for Alzheimer's disease: 18-month results announced

Survey reveals Gamunex as preferred IGIV therapy among neurologists

Survey reveals Gamunex as preferred IGIV therapy among neurologists

Octapharma AG submits Biological License Application for its octagam(R) 10% to FDA

Octapharma AG submits Biological License Application for its octagam(R) 10% to FDA

FDA grants approval to Talecris Biotherapeutics for Gamunex for neurological disorder CIDP

FDA grants approval to Talecris Biotherapeutics for Gamunex for neurological disorder CIDP

FDA approves Gamunex for chronic inflammatory demyelinating polyneuropathy

FDA approves Gamunex for chronic inflammatory demyelinating polyneuropathy

The muscle supplement creatine is safe, but not effective, in pediatric neuromuscular disease

The muscle supplement creatine is safe, but not effective, in pediatric neuromuscular disease